PMID- 38178854
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240106
IS  - 1319-0164 (Print)
IS  - 2213-7475 (Electronic)
IS  - 1319-0164 (Linking)
VI  - 32
IP  - 1
DP  - 2024 Jan
TI  - Implication of MAPK, Lipocalin-2, and Fas in the protective action of liposomal 
      resveratrol against isoproterenol-induced kidney injury.
PG  - 101907
LID - 10.1016/j.jsps.2023.101907 [doi]
LID - 101907
AB  - BACKGROUND AND OBJECTIVE: Isoproterenol (ISO) is a non-selective beta-adrenergic 
      receptor agonist. It can be used to treat bradycardia and cardiogenic shock. 
      Despite its usefulness, the overstimulation of beta-receptors by ISO can cause 
      "cardiorenal syndrome," a term used to describe heart and kidney damage. 
      Resveratrol (RES), a natural polyphenol, has marked anti-inflammatory and 
      antioxidant activities. The present work was designed to study the protective 
      efficacy of liposomal resveratrol (L-RES) against ISO-induced kidney injury. 
      MATERIALS AND METHODS: The kidney injury was induced in rats by administering ISO 
      (50 mg/kg, s.c.) twice a week for 2 weeks. RES and L-RES were administered at a 
      dose (20 mg/kg/ day, p.o.) along with ISO for 2 weeks. Inflammatory and apoptotic 
      biomarkers were analyzed, which were validated using histochemical analysis. 
      RESULTS: ISO caused renal dysfunction, which manifested as elevated urea, 
      creatinine and uric acid, besides cystatin c and MAPK protein overexpression. In 
      addition, ISO induced gene expression of Fas and lipocalin-2 and provoked genomic 
      DNA fragmentation in renal tissues as compared with the control group. 
      Histological examination confirmed morphological alterations of the kidney 
      tissues obtained from the ISO group. Concurrent treatment of either RES or L-RES 
      with ISO significantly ameliorated kidney damage as demonstrated by the 
      improvement of all measured parameters with the best results for L-RES. The 
      histopathological findings were correlated with the above biochemical parameters. 
      CONCLUSION: L-RES could be a promising approach for the prevention of kidney 
      injury induced by ISO, most likely via the downregulation of MAPK, cystatin c, 
      Fas, and lipocalin-2.
CI  - (c) 2023 The Author(s).
FAU - Alhusaini, Ahlam M
AU  - Alhusaini AM
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, P.O Box 22452, Riyadh 11495, Saudi Arabia.
FAU - Alshehri, Samiyah M
AU  - Alshehri SM
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, P.O Box 22452, Riyadh 11495, Saudi Arabia.
FAU - Sarawi, Wedad S
AU  - Sarawi WS
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, P.O Box 22452, Riyadh 11495, Saudi Arabia.
FAU - Alghibiwi, Hanan K
AU  - Alghibiwi HK
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, P.O Box 22452, Riyadh 11495, Saudi Arabia.
FAU - Alturaif, Sumayya A
AU  - Alturaif SA
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, P.O Box 22452, Riyadh 11495, Saudi Arabia.
FAU - Al Khbiah, Reema A
AU  - Al Khbiah RA
AD  - Pharm D Program, College of Pharmacy, King Saud University, P.O Box 22452, Riyadh 
      11495, Saudi Arabia.
FAU - Alali, Shog M
AU  - Alali SM
AD  - Pharm D Program, College of Pharmacy, King Saud University, P.O Box 22452, Riyadh 
      11495, Saudi Arabia.
FAU - Alsaif, Shaikha M
AU  - Alsaif SM
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O Box 
      22452, Riyadh 11495, Saudi Arabia.
FAU - Alsultan, Ebtesam N
AU  - Alsultan EN
AD  - Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O Box 
      22452, Riyadh 11495, Saudi Arabia.
FAU - Hasan, Iman H
AU  - Hasan IH
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, P.O Box 22452, Riyadh 11495, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20231210
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi 
      Pharmaceutical Society
JID - 9705695
PMC - PMC10764257
OTO - NOTNLM
OT  - Cystatin c
OT  - Fas
OT  - Isoproterenol
OT  - L-resveratrol
OT  - Lipocalin-2
OT  - MAPK
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/01/05 06:42
MHDA- 2024/01/05 06:43
PMCR- 2023/12/10
CRDT- 2024/01/05 03:44
PHST- 2023/11/12 00:00 [received]
PHST- 2023/12/05 00:00 [accepted]
PHST- 2024/01/05 06:43 [medline]
PHST- 2024/01/05 06:42 [pubmed]
PHST- 2024/01/05 03:44 [entrez]
PHST- 2023/12/10 00:00 [pmc-release]
AID - S1319-0164(23)00402-4 [pii]
AID - 101907 [pii]
AID - 10.1016/j.jsps.2023.101907 [doi]
PST - ppublish
SO  - Saudi Pharm J. 2024 Jan;32(1):101907. doi: 10.1016/j.jsps.2023.101907. Epub 2023 
      Dec 10.